Bambusa Therapeutics has completed an oversubscribed Series A-2 financing round at a significant valuation increase, marking a major milestone as the Boston-based biotechnology company accelerates the development of its next wave of bispecific antibody programs. The clinical-stage company, which focuses on advancing transformative therapies for immunology and inflammation, secured expanded participation from all existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners, Salvia, Janus Henderson Investors, Invus, ADAR1 Capital Management, and Dawn Biopharma, an investment platform controlled by KKR. Their sustained support reflects increased confidence in the company’s bispecific platform, executional strength, and growing clinical momentum.
Funding from the Series A-2 round will propel the advancement of BBT003 and BBT004, enabling the company to maintain its rapid pace of moving assets from concept to clinical evaluation. Bambusa has already demonstrated its ability to advance programs efficiently, reaching its first two bispecific candidates, BBT001 and BBT002, from development candidates to clinical proof-of-concept within only 18 months. Both have now entered Phase I trials in dermatology and respiratory indications, supporting the company’s goal of reshaping treatment options across a broad range of immunology and inflammation conditions. The next wave of programs, BBT003 and BBT004, will target gastroenterology and rheumatology indications.
The fresh capital will support several key priorities, including advancing BBT003 and BBT004 through IND-enabling studies and into initial clinical trials, expanding Bambusa’s bispecific antibody platform into additional immunology and inflammation indications, and strengthening its development infrastructure as the company prepares for a data-rich 2026 with more than ten expected clinical readouts.
Bambusa’s proprietary platform leverages half-life extension technology and high-concentration subcutaneous delivery to deliver next-generation medicines that improve patient outcomes across a spectrum of chronic inflammatory diseases. Its emerging pipeline includes first-in-class bispecific antibodies designed to set new standards of efficacy and convenience in areas of high unmet need.
KEY QUOTES
“In just 18 months, our team has advanced two bispecific programs, BBT001 and BBT002, from development candidate to clinical proof-of-concept, an unprecedented pace in I&I biologics, demonstrating what a small, highly coordinated team can achieve in a short period of time. This new financing enables us to apply that same momentum to BBT003 and BBT004. Closing the round at a significantly increased valuation is a clear reflection of the strength of our data, the speed and quality of our execution, and the deep conviction from our investors. 2026 will be a catalyst-rich year for Bambusa with more than 10 clinical readouts across multiple I&I indications.”
Dr. Shanshan Xu, Founder and Chief Executive Officer, Bambusa Therapeutics
“RA Capital Management is delighted to continue to support Bambusa as they progress their portfolio of potentially best-in-disease bispecific antibodies for various I&I indications deeper into the clinic. In the nine months since we led the Series A-1 financing, we have been thrilled with the rapid and flawless execution delivered by the Bambusa team. Over the next year we eagerly look forward to the extensive clinical data sets that will highlight the immense value across the Bambusa portfolio.”
Dr. Derek DiRocco, Partner, RA Capital Management
